Skip to main content

Rhino Novi Inc. Acquires BioLife Sciences

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ Rhino Novi Inc. (OTC Markets: RNOV) announces that it has entered into a binding agreement for the purchase of Biolife Sciences Corp. a Canadian company (“BioLife”). Biolife develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. Products include disinfecting wipes, UV sterilization technology, electrostatic disinfection services, anti-microbial textiles, and touchless vending/marketplaces.The agreement calls for the issuance of 35,751,380 RNOV shares to BioLife’s current shareholders, the cancelation of 25,000,000 shares held by current RNOV shareholders, and transactional expenses for up to $50,000 CDN, in exchange for 100% of the shares of BioLife, which will become a wholly-owned subsidiary of Rhino Novi Inc. Upon completion of the agreement, all current officers and directors of BioLife will be appointed to the board of RNOV.RNOV has filed a corporate action with FINRA to change its name to BioLife Sciences Corp. and has filed articles of amendment with the Nevada State. The corporate action is currently pending with FINRA.About Rhino Novi Inc. Rhino Novi Inc. (OTC Markets: RNOV) operates through its wholly owned subsidiary, BioLife Sciences Corp., located in Ontario, Canada. The company specializes in moving innovative products from the lab or small scale production into wider market adoption. Its core business develops, licenses and distributes antibacterial products, non-contact human temperature screening technology, and touchless vending/marketplaces.www.biolifesciences.com                  
ir@biolifesciences.com                     
+1 775 9810270

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.